21:18 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma In vitro , cell culture and mouse studies identified a quinazolinamine-based STK19 inhibitor that could help treat NRAS-mutant melanoma. In vitro screening of a small molecule library and optimization of the top hit...
18:54 , Jan 4, 2019 |  BC Week In Review  |  Company News

Codiak, Jazz to develop exosomes against tricky oncogenes

Codiak BioSciences Inc. (Cambridge, Mass.) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) partnered to develop exosome therapies for hard-to-treat cancers. Jazz gains exclusive, worldwide rights to develop, manufacture and commercialize exosome candidates against five oncogene targets for...
21:28 , Jan 3, 2019 |  BC Extra  |  Company News

Codiak, Jazz to develop exosomes against tricky oncogenes

Codiak BioSciences Inc. (Cambridge, Mass.) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) partnered to develop exosome therapies for hard-to-treat cancers. Jazz gains exclusive, worldwide rights to develop, manufacture and commercialize exosome candidates against five oncogene targets for...
19:45 , Nov 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
17:31 , Sep 26, 2018 |  BC Innovations  |  Distillery Techniques

Assay and screens; other

TECHNOLOGY: Cell-free assays; computational models A computational model based on mutations in plasma cell-free DNA (cfDNA) could help predict the time to progression in mCRC patients treated with anti-EGFR therapies. Construction of the model involves...
16:10 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Cell culture studies identified a triple KRAS/NRAS/HRAS inhibitor that could help treat KRAS-mutant colorectal cancer and NRAS-mutant non-small cell lung cancer (NSCLC). Screening of a small molecule library, structure-based optimization...
22:49 , Aug 10, 2018 |  BC Extra  |  Preclinical News

New approach could identify Ras-blocking small molecules

With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues devised a way to find small molecules that have the same qualities as Ras inhibitors too large to access...
21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer In vitro , cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme...
16:49 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
18:21 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer In vitro and cell culture studies identified a quindoline-based stabilizer of the NRAS mRNA G-quadruplex region that could help treat cancer. Chemical synthesis and in vitro testing in binding and enzyme activity assays...